HLA class ii tetramers reveal tissue-specific regulatory t cells that suppress T-cell responses in breast carcinoma patients

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Schmidt, Hans Henning ^a   Ge, Yingzi ^a   Hartmann, Felix J ^a   Conrad, Heinke ^a,b   Klug, Felix ^a   Nittel, Sina ^a,b   Bernhard, Helga ^a,b,c   Domschke, Christoph ^a,d   Schuetz, Florian ^d   Sohn, Christof ^d   Beckhove, Philipp ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM DARMSTADT   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Breast cancer; HLA Class II; Mammaglobin; Multimer; Regulatory T cells; Suppression; Tetramer; Tregs; Tumor specific T cells

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DRB1 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MAMMAGLOBIN A; TETRAMER; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL MONITORING; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TISSUE SPECIFICITY; TUMOR IMMUNITY;

EID: 84886943825     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24962     Document Type: Article

References (31)

1. Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009; 69:8420-8; PMID:19843863; http://dx.doi. org/10.1158/0008-5472.CAN-09-1627
2. Domschke C, Schuetz F, Sommerfeldt N, Rom J, Scharf A, Sohn C, et al. Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients. Cancer Immunol Immunother 2010; 59:479-86; PMID:19957084; http://dx.doi.org/10.1007/s00262-009-0801-9
3. Sommerfeldt N, Schütz F, Sohn C, Förster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006; 66:8258-65; PMID:16912206; http://dx.doi. org/10.1158/0008-5472.CAN-05-4201
4. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7:452-8; PMID:11283672; http://dx.doi.org/10.1038/86523
5. Schuetz F, Ehlert K, Ge Y, Schneeweiss A, Rom J, Inzkirweli N, et al. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 2009; 58:887-900; PMID:18998129; http://dx.doi.org/10.1007/s00262-008-0605-3
6. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, et al. Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer. Am J Clin Oncol 2012; In press; PMID:22495453; http://dx.doi.org/10.1097/COC.0b013e3182467d90
7. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
8. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68; PMID:9858522; http://dx.doi. org/10.1084/jem.188.12.2357
9. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721-8; PMID:16010587; http://dx.doi.org/10.1007/s00262-004-0653-2
10. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-700; PMID:16818676; http://dx.doi. org/10.1084/jem.20060468
11. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; http://dx.doi. org/10.1200/JCO.2006.05.9584
12. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98:1089-99; PMID:12942579; http://dx.doi. org/10.1002/cncr.11618
13. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
14. Samy ET, Parker LA, Sharp CP, Tung KS. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med 2005; 202:771-81; PMID:16172257; http://dx.doi.org/10.1084/jem.20041033
15. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199:1467-77; PMID:15184500; http://dx.doi.org/10.1084/jem.20040180
16. Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology 2012; 1:642-8; PMID:22934256; http://dx.doi.org/10.4161/onci.20298
17. Watson MA, Fleming TP. Mammaglobin, a mammaryspecific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56:860-5; PMID:8631025
18. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets 2004; 4:531-42; PMID:15462037; http://dx.doi. org/10.2174/1568009043332862
19. Li G, Zhang J, Jin K, He K, Wang H, Lu H, et al. Human mammaglobin: a superior marker for reversetranscriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med 2011; 5:249-60; PMID:21473729; http://dx.doi.org/10.2217/bmm.11.20
20. Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 2004; 37:249-57; PMID:15003725; http://dx.doi. org/10.1016/j.clinbiochem.2003.11.005
21. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21; PMID:19809157
22. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9; PMID:10602881; http://dx.doi. org/10.1007/s002510050595
23. Viehl CT, Frey DM, Phommaly C, Chen T, Fleming TP, Gillanders WE, et al. Generation of mammaglobin- A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. Breast Cancer Res Treat 2008; 109:305-14; PMID:17653857; http://dx.doi.org/10.1007/s10549-007-9657-x
24. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201:723-35; PMID:15753206; http://dx.doi.org/10.1084/jem.20041982
25. Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, et al. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A 2010; 107:7437-42; PMID:20368442; http://dx.doi.org/10.1073/pnas.1001322107
26. Redjimi N, Duperrier-Amouriaux K, Raimbaud I, Luescher I, Dojcinovic D, Classe JM, et al. NY-ESO- 1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment. PLoS One 2011; 6:e22845; PMID:21829534; http://dx.doi. org/10.1371/journal.pone.0022845
27. Nepom GT. MHC class II tetramers. J Immunol 2012; 188:2477-82; PMID:22389204; http://dx.doi. org/10.4049/jimmunol.1102398
28. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One 2012; 7:e48424; PMID:23110239; http://dx.doi.org/10.1371/journal. pone.0048424
29. Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 2009; 69:8085-93; PMID:19808957; http://dx.doi.org/10.1158/0008-5472.CAN-09-2226
30. Kalandadze A, Galleno M, Foncerrada L, Strominger JL, Wucherpfennig KW. Expression of recombinant HLA-DR2 molecules. Replacement of the hydrophobic transmembrane region by a leucine zipper dimerization motif allows the assembly and secretion of soluble DR alpha beta heterodimers. J Biol Chem 1996; 271:20156-62; PMID:8702739; http://dx.doi. org/10.1074/jbc.271.33.20156
31. Ye M, Kasey S, Khurana S, Nguyen NT, Schubert S, Nugent CT, et al. MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4(+) T cells in healthy volunteers. Hum Immunol 2004; 65:507-13; PMID:15172451; http://dx.doi.org/10.1016/j. humimm.2004.02.019